Revance Therapeutics sinks amid `going concern' disclosure

seekingalpha11-08

Visivasnc/iStock via Getty Images Revance Therapeutics (NASDAQ:RVNC) plunged 16% in after hours trading after the company disclosed that there's substantial doubt about its ability to contine as a "...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481013105?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/860617994/image_860617994.jpg?io=getty-c-w750","is_english":true,"pubTime":"2024-11-08 09:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481013105","market":"other","top_or_hot":-1,"title":"Revance Therapeutics sinks amid `going concern' disclosure","media":"seekingalpha","content":"<div>\n<p>Visivasnc/iStock via Getty Images Revance Therapeutics (NASDAQ:RVNC) plunged 16% in after hours trading after the company disclosed that there's substantial doubt about its ability to contine as a \"...</p>\n\n<a href=\"https://seekingalpha.com/news/4263827-revance-therapeutics-sinks-amid-going-concern-disclosure\">Source Link</a>\n\n</div>\n","source":"seekingalpha_trending_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revance Therapeutics sinks amid `going concern' disclosure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevance Therapeutics sinks amid `going concern' disclosure\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 09:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4263827-revance-therapeutics-sinks-amid-going-concern-disclosure><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Visivasnc/iStock via Getty Images Revance Therapeutics (NASDAQ:RVNC) plunged 16% in after hours trading after the company disclosed that there's substantial doubt about its ability to contine as a \"...</p>\n\n<a href=\"https://seekingalpha.com/news/4263827-revance-therapeutics-sinks-amid-going-concern-disclosure\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://seekingalpha.com/news/4263827-revance-therapeutics-sinks-amid-going-concern-disclosure","article_id":"2481013105","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/860617994/image_860617994.jpg?io=getty-c-w750"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481013105","pubTimestamp":1731030344,"sourceInfo":{"source_id":"seekingalpha_trending_news","name":"Seeking Alpha Trending News"},"weMediaInfo":null,"summary":"Visivasnc/iStock via Getty Images Revance Therapeutics (NASDAQ:RVNC) plunged 16% in after hours trading after the company disclosed that there's substantial doubt about its ability to contine as a \"go","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4007":"制药","RVNC":"Revance Therapeutics Inc","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4585":"ETF&股票定投概念"},"translate_title":"Revance Therapeutics因“持续经营”披露而陷入困境","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVNC":1},"content_text":"Visivasnc/iStock via Getty Images Revance Therapeutics (NASDAQ:RVNC) plunged 16% in after hours trading after the company disclosed that there's substantial doubt about its ability to contine as a \"going concern.\" The company also missed Q3 revenue estimates and withdrew its 2024 guidance and said there's a potential that Crown Laboratories deal may be terminated. \"Management has concluded there is substantial doubt about our ability to continue as a going concern,\" Revance said in a 10-Q filing on Thursday. \"In order to mitigate the substantial doubt to continue as a going concern, we may be required to refinance our debt, conduct additional financings, restructure operations, sell assets or reduce our operating expenses.\" The going concern disclosure comes as Crown Laboratories, which agreed to purchase Revance (RVNC) for $6.66 in August, further extended a tender offer for the company to Nov. 12. Revance stock surged 26% last Monday after an earlier tender extension as some investors feared that the deal may be scuttled. The extension came after Revance (RVNC) and Teoxane came to a settlement last month.  Revance (RVNC) disclosed in the 10-Q filing on Thursday that Crown is dissatisfied with Revance's entry into the Teoxane agreement and may decide to terminate the merger agreement or reach a settlement.  \"While the parties continue their discussions, Crown may assert claims related to the Merger Agreement or take other action in connection with the Company’s entry into the Teoxane Agreements, including by seeking to unilaterally terminate the Merger Agreement or to otherwise reach a settlement,\" Revance wrote.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481013105"}